• OPEN AN ACCOUNT
Indian Indices
Nifty
16,282.80 112.65
(0.70%)
Sensex
54,746.72 494.19
( 0.91%)
Bank Nifty
35,358.30 263.40
( 0.75%)
Nifty IT
28,481.75 549.20
( 1.97%)
Global Indices
Nasdaq
11,740.65 305.91
(2.68%)
Dow Jones
32,637.19 516.91
(1.61%)
Hang Seng
20,116.20 -55.07
(-0.27%)
Nikkei 225
26,604.84 -72.96
(-0.27%)
Forex
USD-INR
77.37 -0.02
(-0.02%)
EUR-INR
82.66 -0.21
(-0.25%)
GBP-INR
97.01 -0.01
(-0.01%)
JPY-INR
0.61 0.00
(0.02%)

EQUITY - MARKET SCREENER

Tata Motors Ltd
Industry :  Automobiles - LCVs / HCVs
BSE Code
ISIN Demat
Book Value()
500570
INE155A01022
59.7509966
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
TATAMOTORS
0
149997.94
EPS(TTM)
Face Value()
Div & Yield %
0
2
0
 

Sun Pharmaceuticals Industries Ltd
Sun Pharma receives USFDA approval for generic Amphotericin B Liposome for Injection
Dec 15,2021
Sun Pharmaceuticals Industries announced that one of its wholly-owned subsidiaries has received final approval from US FDA for its Abbreviated New Drug Application (ANDA) for generic Amphotericin B Liposome for Injection, 50 mg/vial Single-Dose Vial. The generic product approval is based on AmBisome® Liposome for Injection, 50 mg/vial as a reference product.

Sun Pharma has been granted Competitive Generic Therapy (CGT) designation by US FDA and being the first approved generic, is eligible for 180 days of CGT exclusivity for the product.

As per October 2021 IQVIA Health data, AmBisome® Liposome for Injection, 50mg/vial had annualized sales of approximately US$ 136 million in USA.